Compounds > 6,15-diketo-13,14-dihydroprostaglandin f1alpha
Page last updated: 2024-12-08

6,15-diketo-13,14-dihydroprostaglandin f1alpha

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

6,15-diketo-13,14-dihydroprostaglandin F1alpha: prostacyclin metabolite; RN given refers to (9alpha,11alpha)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID174013
SCHEMBL ID20613687
MeSH IDM0103564

Synonyms (30)

Synonym
LMFA03010013 ,
6,15-dioxo-9s,11r-dihydroxyprostanoic acid
13,14-dihydro-6,15-diketo-pgf1alpha
6,15-ddpf
63983-53-9
6,15-diketo-13,14-dihydro prostaglandin f1alpha
7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-(3-oxooctyl)cyclopentyl]-6-oxoheptanoic acid
prostan-1-oic acid, 9,11-dihydroxy-6,15-dioxo-, (9alpha,11alpha)-
6,15-dioxo-13,14-dihydro-pgf1alpha
6,15-diketo-13,14-dihydro-pgf1alpha
6,15-diketo-13,14-dihydroprostaglandin f1alpha
unii-3woj38o7zb
3woj38o7zb ,
13,14-dihydro-6,15-dioxo-pgf1.alpha.
prostan-1-oic acid, 9,11-dihydroxy-6,15-dioxo-, (9.alpha.,11.alpha.)-
6,15-diketo-13,14-dihydro-pgf1.alpha.
6,15-dioxo-9.alpha.,11.alpha.-dihydroxy-prostan-1-oic acid
6,15-diketo-13,14-dihydro prostaglandin f1.alpha.
6,15-diketo-13,14-dihydro pgf1alpha
7-((1r,2r,3r,5s)-3,5-dihydroxy-2-(3-oxooctyl)cyclopentyl)-6-oxoheptanoic acid
9,11-dihydroxy-6,15-dioxoprostan-1-oic acid
DTXSID60981700
sr-01000946851
SR-01000946851-1
Q27258145
6,15-diketo-13,14-dihydro prostaglandin f1 alpha
SCHEMBL20613687
PD020579
AKOS040755431
6,15-diketo-13,14-dihydro prostaglandin f1??
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (90.91)18.7374
1990's1 (9.09)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.79

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.79 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.27 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.79)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (9.09%)4.05%
Observational0 (0.00%)0.25%
Other10 (90.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
lactic acid
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed). 2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.		1.96102-hydroxy monocarboxylic acidalgal metabolite;
Daphnia magna metabolite
nafazatrom
[no description available]		1.9610
angiotensin ii
Giapreza: injectable form of angiotensin II used to increase blood pressure in adult patients with septic or other distributive shock. Ile(5)-angiotensin II : An angiotensin II that acts on the central nervous system (PDB entry: 1N9V).		2.3620amino acid zwitterion;
angiotensin II		human metabolite
bradykinin
[no description available]		1.9610oligopeptidehuman blood serum metabolite;
vasodilator agent
arachidonic acid
icosa-5,8,11,14-tetraenoic acid : Any icosatetraenoic acid with the double bonds at positions 5, 8, 11 and 14.. arachidonate : A long-chain fatty acid anion resulting from the removal of a proton from the carboxy group of arachidonic acid.		1.9610icosa-5,8,11,14-tetraenoic acid;
long-chain fatty acid;
omega-6 fatty acid		Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
human metabolite;
mouse metabolite
6-ketoprostaglandin f1 alpha
6-Ketoprostaglandin F1 alpha: The physiologically active and stable hydrolysis product of EPOPROSTENOL. Found in nearly all mammalian tissue.. 6-oxoprostaglandin F1alpha : A prostaglandin Falpha that is prostaglandin F1alpha bearing a keto substituent at the 6-position.		3.75110prostaglandins Falphahuman metabolite;
mouse metabolite
thromboxane b2
Thromboxane B2: A stable, physiologically active compound formed in vivo from the prostaglandin endoperoxides. It is important in the platelet-release reaction (release of ADP and serotonin).. thromboxane B2 : A member of the class of thromboxanes B that is (5Z,13E)-thromboxa-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15.		1.9610thromboxanes Bhuman metabolite;
mouse metabolite
12-hydroxy-5,8,10,14-eicosatetraenoic acid
12-Hydroxy-5,8,10,14-eicosatetraenoic Acid: A lipoxygenase metabolite of ARACHIDONIC ACID. It is a highly selective ligand used to label mu-opioid receptors in both membranes and tissue sections. The 12-S-HETE analog has been reported to augment tumor cell metastatic potential through activation of protein kinase C. (J Pharmacol Exp Ther 1995; 274(3):1545-51; J Natl Cancer Inst 1994; 86(15):1145-51)		1.9610
15-hydroxy-5,8,11,13-eicosatetraenoic acid
15-hydroxy-5,8,11,13-eicosatetraenoic acid: potent & selective inhibitor of platelet lipoxygenase; RN given refers to cpd without isomeric designation		1.9610
ConditionIndicatedRelationship StrengthStudiesTrials
Congenital Thrombotic Thrombocytopenic Purpura
[description not available]		01.9610
Purpura, Thrombotic Thrombocytopenic
An acquired, congenital, or familial disorder caused by PLATELET AGGREGATION with THROMBOSIS in terminal arterioles and capillaries. Clinical features include THROMBOCYTOPENIA; HEMOLYTIC ANEMIA; AZOTEMIA; FEVER; and thrombotic microangiopathy. The classical form also includes neurological symptoms and end-organ damage, such as RENAL FAILURE. Mutations in the ADAMTS13 PROTEIN gene have been identified in familial cases.		01.9610
Chronic Kidney Failure
[description not available]		01.9610
Kidney Failure, Chronic
The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.		01.9610
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		0210